A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Exclusion Criteria

• •History of severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
• •Use of zileuton or roflumilast within 6 months prior to screening
• •Maintenance oral corticosteroid therapy, defined as daily or alternate day oral corticosteroid maintenance therapy within the 3 months prior to Visit 1
• •Treatment with systemic (oral, intravenous or intramuscular) corticosteroids within the 4 weeks prior to Visit 1
• •Major episode of infection within 4 weeks prior to Visit 1 or treatment with oral antibiotics within 2 weeks prior to Visit 1
• •Active parasitic infection within the 6 months prior to Visit 1
• •Active tuberculosis requiring treatment within the 12 months prior to Visit 1
• •Known immunodeficiency, including, but not limited to, HIV infection
• •Evidence of acute or chronic hepatitis or known liver cirrhosis
• •History of cystic fibrosis, chronic obstructive pulmonary disease, and/or other clinically significant lung disease other than asthma
• •Known malignancy or current evaluation for a potential malignancy
• •Current smoker or former smoker with a history \>10 pack years
• •History of alcohol, drug or chemical abuse
• •Initiation or change in allergen immunotherapy within 3 months prior to Visit 1
• •Use of biologic therapy including omalizumab during 6 months prior to Visit 1
• •Receipt of live/attenuated vaccine within 4 weeks prior to Visit 1
• •Pregnant or lactating women
• •Body mass index (BMI) \> 38 kg/m2
• •Body weight \< 40 kg